[T2HD Study. Oral anticoagulants and antiplatelet agents: Practices, benefits, and risks in the chronic hemodialysis population. Observational data].

[1]  G. Lip,et al.  Use of the CHA2DS2-VASc and HAS-BLED Scores to Aid Decision Making for Thromboprophylaxis in Nonvalvular Atrial Fibrillation , 2012, Circulation.

[2]  R. Foley,et al.  Cardiovascular mortality in the general population versus dialysis: a glass half full or empty? , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  M. Polaina,et al.  Ischaemic stroke in incident dialysis patients. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  C. White,et al.  Antiplatelet agents for the prevention of arteriovenous fistula and graft thrombosis: a meta analysis , 2010, International journal of clinical practice.

[5]  Frits R Rosendaal,et al.  Cardiovascular and noncardiovascular mortality among patients starting dialysis. , 2009, JAMA.

[6]  R. Thadhani,et al.  Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. , 2009, Journal of the American Society of Nephrology : JASN.

[7]  V. Fuster,et al.  Cardiovascular risk factors in patients with chronic kidney disease , 2009, Nature Reviews Cardiology.

[8]  G. Beck,et al.  Effect of dipyridamole plus aspirin on hemodialysis graft patency. , 2009, The New England journal of medicine.

[9]  D. Fergusson,et al.  Antiplatelet medications in hemodialysis patients: a systematic review of bleeding rates. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[10]  G. Breithardt,et al.  Dilemmas in the management of atrial fibrillation in chronic kidney disease. , 2009, Journal of the American Society of Nephrology : JASN.

[11]  R. Thadhani,et al.  Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. , 2009, Journal of the American Society of Nephrology : JASN.

[12]  J. Wetmore,et al.  The ABCs of cardioprotection in dialysis patients: a systematic review. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  J. Kaufman,et al.  Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. , 2008, JAMA.

[14]  R. Califf,et al.  The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. , 2008, American heart journal.

[15]  Samuel G. Johnson,et al.  Outcomes associated with combined antiplatelet and anticoagulant therapy. , 2008, Chest.

[16]  L. Vercaigne,et al.  Does warfarin safely prevent clotting of hemodialysis catheters? a review of efficacy and safety. , 2007, Seminars in dialysis.

[17]  M. Allon,et al.  Current management of vascular access. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[18]  K. Fischer.  Essentials of anticoagulation in hemodialysis , 2007, Hemodialysis international. International Symposium on Home Hemodialysis.

[19]  H. Trimarchi,et al.  Clopidogrel Diminishes Hemodialysis Access Graft Thrombosis , 2005, Nephron Clinical Practice.

[20]  M. Valsecchi,et al.  Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  B. Kestenbaum,et al.  Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients. , 2003, Kidney international.

[22]  P. Peduzzi,et al.  Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. , 2003, Journal of the American Society of Nephrology : JASN.

[23]  L. Dember,et al.  Thrombosis in End‐Stage Renal Disease , 2003, Seminars in dialysis.

[24]  B. Sobel,et al.  Biphasic effects of hemodialysis on platelet reactivity in patients with end-stage renal disease: a potential contributor to cardiovascular risk. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  F. Kronenberg,et al.  Coumarins and survival in incident dialysis patients. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[26]  K. Jurk,et al.  Platelets: Physiology and Biochemistry , 2005, Seminars in thrombosis and hemostasis.